Jonathan Lewis, MD, PhD

Dr. Lewis is Chairman of Dugri Inc and serves on the board and advisory boards of several non-profit and tech and biotech companies. He also serves as Chief Strategy Officer for Syncromune, a cancer immunotherapy company that is developing intratumoral multitarget neoantigen T Cell activation. He served as Professor of Surgery and Medicine at Memorial Sloan-Kettering Cancer Center. While at Sloan-Kettering he completed his surgical oncology fellowship, and a post-doctoral fellowship in immunology. He was active in soft tissue sarcoma surgery, treatment and clinical research, and laboratory and translational research in immunotherapy and EGF family signal transduction. Prior to Sloan Kettering he completed his general surgical residency and PhD in growth factor signal transduction at Yale. He lead global translational and clinical research in cancer and has helped develop several new drugs in cancer. He has received numerous honors and awards in medicine and science, including the ASCO Young Investigator Award, the Kristen Carr Fellowship, the Yale University Ohse Fellowship, the Royal College of Surgeons Trubshaw Medal, and the Sarcoma Foundation of America Hope and Vision Award. He has served as Director and Chair of several biotechnology companies. He serves as a Director on the Board of POPPA (the Police Organization Providing Peer Assistance) of the New York Police Department (NYPD). He also served on the Medical Advisory Board of the Sarcoma Foundation of America, and the Scientific Advisory Board of the Combat Wound Initiative and Limb Salvage Program of the Henry Jackson Foundation for the Advancement of Military Medicine. Dr. Lewis was elected the first Life Trustee of the Hope Funds for Cancer Research on December 1, 2015, having formerly served as a board member, Chair of the Scientific Advisory Council, and as the second Chairman of the Board of Trustees.